CJASN
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clin J Am Soc Nephrol 2: S36-S46, 2007
© 2007 American Society of Nephrology
doi: 10.2215/CJN.00920207
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bohl, D. L.
Right arrow Articles by Brennan, D. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bohl, D. L.
Right arrow Articles by Brennan, D. C.

Viruses and Diseases of the Kidney

BK Virus Nephropathy and Kidney Transplantation

Daniel L. Bohl, and Daniel C. Brennan

Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri

Address correspondence to: Dr. Daniel C. Brennan, Department of Medicine, Transplant Nephrology, Washington University, Barnes-Jewish Hospital, 6107 Queeny Tower, One Barnes-Jewish Hospital Plaza, St. Louis, MO 63110. Phone: 314-362-8351; Fax: 314-361-4197; E-mail brennan{at}wudosis.wustl.edu

Nephropathy from BK virus (BKV) infection is an evolving challenge in kidney transplant recipients. It is the consequence of modern potent immunosuppression aimed at reducing acute rejection and improving allograft survival. Untreated BKV infections lead to kidney allograft dysfunction or loss. Decreased immunosuppression is the principle treatment but predisposes to acute and chronic rejection. Screening protocols for early detection and prevention of symptomatic BKV nephropathy have improved outcomes. Although no approved antiviral drug is available, leflunomide, cidofovir, quinolones, and intravenous Ig have been used. Retransplantation after BKV nephropathy has been successful.




This article has been cited by other articles:


Home page
 J. Virol.Home page
E. C. Goodwin, W. J. Atwood, and D. DiMaio
High-Throughput Cell-Based Screen for Chemicals That Inhibit Infection by Simian Virus 40 and Human Polyomaviruses
J. Virol., June 1, 2009; 83(11): 5630 - 5639.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
J. R. Abend, A. E. Joseph, D. Das, D. B. Campbell-Cecen, and M. J. Imperiale
A truncated T antigen expressed from an alternatively spliced BK virus early mRNA
J. Gen. Virol., May 1, 2009; 90(5): 1238 - 1245.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
R. Hilton and C. Y. W. Tong
Antiviral therapy for polyomavirus-associated nephropathy after renal transplantation
J. Antimicrob. Chemother., November 1, 2008; 62(5): 855 - 859.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
J. K Wu and M. T Harris
Use of Leflunomide in the Treatment of Polyomavirus BK-Associated Nephropathy
Ann. Pharmacother., November 1, 2008; 42(11): 1679 - 1685.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Society of Nephrology.